



Universiteit
Leiden
The Netherlands

The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy

, T.T. le; Lim, V.; Ibrahim, R.; Teo, M.T.; Bryant, J.; Ang, B.; ... ; Chin, C.W.L.

Citation

Lim, V., Ibrahim, R., Teo, M. T., Bryant, J., Ang, B., Su, B., ... Chin, C. W. L. (2021). The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy. *European Heart Journal - Cardiovascular Imaging*, 22(6), 670-679.
doi:10.1093/ehjci/jeaa040

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3279735>

Note: To cite this publication please use the final published version (if applicable).

The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy

Thu-Thao Le^{1,2}, Vanessa Lim¹, Rositaa Ibrahim^{1,3}, Muh-Tyng Teo¹, Jennifer Bryant¹, Briana Ang¹, Boyang Su¹, Tar-Choon Aw⁴, Chi-Hang Lee¹, Jeroen Bax⁵, Stuart Cook^{1,2}, and Calvin W.L. Chin^{1,2*} 

¹Department of Cardiology, National Heart Center Singapore, Singapore; ²Cardiovascular ACP, Duke-NUS Medical School, Singapore; ³Department of Radiology, Penang General Hospital, Penang, Malaysia; ⁴Department of Laboratory Medicine, Changi General Hospital, Singapore; and ⁵Faculty in Medicine, Leiden University, the Netherlands

Received 24 June 2019; editorial decision 25 February 2020; accepted 3 March 2020; online publish-ahead-of-print 7 April 2020

Aims

Hypertensive left ventricular hypertrophy (LVH) is associated with increased cardiovascular events. We previously developed the remodelling index (RI) that incorporated left ventricular (LV) volume and wall-thickness in a single measure of advanced hypertrophy in hypertensive patients. This study examined the prognostic potential of the RI in reference to contemporary LVH classifications.

Methods and results

Cardiovascular magnetic resonance was performed in 400 asymptomatic hypertensive patients. The newly derived RI ($\frac{3 \times \text{EDV}}{t}$, where EDV is LV end-diastolic volume and t is the maximal wall thickness across 16 myocardial segments) stratified hypertensive patients: no LVH, LVH with normal RI (LVH_{Normal-RI}), and LVH with low RI (LVH_{Low-RI}). The primary outcome was a composite of all-cause mortality, acute coronary syndromes, strokes, and decompensated heart failure. LVH_{Low-RI} was associated with increased LV mass index, fibrosis burden, impaired myocardial function and elevated biochemical markers of myocardial injury (high-sensitive cardiac troponin I), and wall stress. Over 18.3 ± 7.0 months (601.3 patient-years), 14 adverse events occurred (2.2 events/100 patient-years). Patients with LVH_{Low-RI} had more than a five-fold increase in adverse events compared to those with LVH_{Normal-RI} (11.6 events/100 patient-years vs. 2.0 events/100 patient-years, respectively; log-rank $P < 0.001$). The RI provided incremental prognostic value over and above a model consisting of clinical variables, LVH and concentricity; and predicted adverse events independent of clinical variables, LVH, and other prognostic markers. Concentric and eccentric LVH were associated with adverse prognosis (log-rank $P = 0.62$) that was similar to the natural history of hypertensive LVH (5.1 events/100 patient-years).

Conclusion

The RI provides prognostic value that improves risk stratification of hypertensive LVH.

Keywords

hypertensive heart disease • left ventricular hypertrophy • cardiac remodelling • cardiovascular magnetic resonance

Introduction

Left ventricular hypertrophy (LVH) is prevalent in 16–74% of patients with essential hypertension and it is well-established that hypertensive LVH is associated with adverse cardiovascular outcomes, above and beyond blood pressure effects.^{1–3}

Conventionally, four geometric patterns have been recommended to describe the left ventricular (LV) response to

hypertension: normal, concentric remodelling, concentric, and eccentric hypertrophy.^{4,5} Although both concentric and eccentric hypertrophy were associated with worse outcomes, the incremental value of geometry beyond LV mass remains uncertain.^{6–11} Moreover, both concentric and eccentric hypertrophy were associated with similar LV mass index, fibrosis burden, and biochemical markers of myocardial injury and cardiac decompensation.¹² These observations may suggest that the risk of adverse cardiovascular

* Corresponding author. Tel: +65 (8) 321 9867. E-mail: cchin03m@gmail.com

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

outcomes is increased once hypertensive LVH develops, regardless of the geometric patterns. However, it also raises the question of whether there are other strategies to improve risk stratification of hypertensive LVH.

Recently, we have derived a cardiovascular magnetic resonance (CMR) marker of advanced hypertrophy (*remodelling index*; $RI = \frac{\sqrt[3]{EDV}}{t}$, where EDV is the end-diastolic volume and t is the maximal wall thickness across 16 myocardial segments; Figure 1) from a biophysical model of LaPlace's Law of wall stress.¹² This measure is distinctive from conventional measures of concentricity. In patients with hypertensive LVH, an abnormally low RI was associated with the highest LV mass, increased non-ischaemic myocardial fibrosis, impaired diastolic function, and elevated biochemical markers of myocardial injury and cardiac decompensation. These findings demonstrated the potential of the RI in risk stratifying hypertensive patients. In this study, we aim to examine the mechanistic and prognostic potential of the RI in asymptomatic patients with hypertension in reference to conventional LVH classifications. We hypothesize that the RI is a measure that reflects the heterogeneous remodelling process of hypertensive LVH; and it can improve LVH risk stratification.

Methods

Patient populations

Asymptomatic patients with essential hypertension comprised of participants from the REMODEL observational study (clinicaltrials.gov identifier: NCT02670031). Patients with secondary causes of hypertension, clinically diagnosed coronary artery disease (previous myocardial infarction, $\geq 70\%$ stenosis on invasive angiography, or positive cardiac stress tests), previous cerebrovascular events, atrial fibrillation, and heart failure were excluded. Patients with incidental myocardial infarction and significant valvular heart disease ($\geq$ moderate severity in valvular regurgitation or aortic stenosis) on CMR were excluded from this study. Blood pressure in the REMODEL cohort was recorded with 24-h ambulatory blood pressure monitors.

The study was conducted in accordance to the Declaration of Helsinki and approved by the local research ethics committee. Written informed consent was obtained from all study participants.

Clinical outcomes

The primary outcome was a composite of all-cause mortality, acute coronary syndromes (unstable angina and myocardial infarction), strokes and acute decompensated heart failure (first heart failure hospitalization diagnosed based on contemporary guidelines). Patients were followed between February 2016 and December 2018. An experienced cardiologist (C.W.L.C.) who was blinded to the imaging data, adjudicated all events by independent review of patient's healthcare records.

CMR protocol and image analysis

CMR was performed in all hypertensive patients with a standardized imaging protocol (Siemens Aera 1.5 T, Siemens Healthineers, Erlangen, Germany). Balanced steady-state free precision cines were acquired in the standard long-axis (two-, three-, and four-chamber) planes, and right ventricular (RV) long-axis view aligned with the tricuspid inflow and RV outflow tract. Short-axis cines extending from the atrioventricular ring to the apex were obtained to cover the entire left and right ventricles (acquired voxel size: 1.6 mm $\times$ 1.3 mm $\times$ 8.0 mm; 2 mm gap; 30 phases




Figure 1 Myocardial wall stress and the development of the remodelling index.

per cardiac cycle). Flow at the ascending aorta was assessed using standard through-plane breath-hold segmented phase-contrast imaging at the level of the pulmonary artery bifurcation (acquired voxel size: 1.8 mm $\times$ 1.8 mm $\times$ 6.0 mm; 50 phases per cardiac cycle). The encoding velocity was individually adjusted according to the velocity of blood flow starting from 150 cm/s.

Myocardial fibrosis was assessed using two approaches: late gadolinium-enhanced imaging and myocardial T1 mapping. For the assessment of non-ischaemic replacement fibrosis, late gadolinium-enhanced imaging was performed ~ 8 min after administration of 0.1 mmol/kg of gadobutrol (Gadovist; Bayer Pharma AG, Germany). An inversion-recovery fast gradient echo sequence was used and the inversion time was optimized to achieve appropriate nulling of the myocardium. Myocardial T1 mapping based on the Modified Look-Locker inversion-recovery sequence was used as a more sensitive measure of diffuse myocardial fibrosis.^{13,14} Extracellular volume fraction (ECV) was estimated from the native and 15-min post-contrast T1 map,¹⁵ analysed using the T1 mapping module (CVI42, Circle Cardiovascular Imaging, Calgary, Canada). Interstitial volumes were defined as a product of ECV and myocardial volume (myocardial volume = LV mass/1.05 g/mL). We had previously demonstrated its excellent correlation with histological fibrosis and prognostic value in patients with aortic stenosis.¹⁶

Cardiac volumes, function, LV mass, and myocardial strain were analysed using CVI42 (Circle Cardiovascular Imaging, Calgary, Canada) at our NHRIS CMR Core Laboratory. Myocardial mass was estimated at end-diastole and corroborated at end-systole: (total epicardial volume - total endocardial volume) $\times$ 1.05 g/mL. Circumferential and radial strain were measured in the short-axis cine images, while longitudinal strain was measured in the long-axis views.¹⁷ Aortic peak flow acceleration values were the first derivative of the instantaneous flow measurements. Peak flow acceleration was validated as a non-invasive marker of LV contractility in echocardiographic studies.^{18,19} All image analyses were performed by three trained investigators (V.Z.K.L., M.T., and R.I.) who were blinded to the other clinical and outcome data.

Echocardiography

Echocardiography (ProSound F75; Hitachi Aloka Medical Ltd., Tokyo, Japan) was performed in the patients. Cardiac dimensions and function were assessed according to the European Association of Echocardiography/American Society of Echocardiography guidelines.²⁰

Relative wall thickness (RWT) was estimated as two times posterior wall thickness divided by LV diastolic diameter on M-mode, measured by a single trained sonographer.²⁰

Classifications of LVH

We examined the prognostic value of two LVH classifications in this study. The conventional approach classified LV geometry based on LV mass and concentricity (LV mass/end-diastolic volume; M/V ratio): normal geometry, concentric remodelling, concentric, and eccentric hypertrophy.²⁰ The second approach stratified hypertensive LVH based on the RI. Three remodelling patterns were described: no LVH, hypertensive LVH with normal RI, and hypertensive LVH with low RI.¹² LVH and abnormal M/V were diagnosed according to age- and sex-specific reference ranges we had established in Asians.²¹

Cardiac biochemical markers

Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP; proBNP II STAT, Roche Diagnostics, Pensberg, Germany) was assayed using electrochemiluminescence immunoassay on the Cobas E602 analyzer (Roche Diagnostics Asia-Pacific, Singapore). Serum high-sensitive cardiac troponin I (hsTnI; ARCHITECT STAT high-sensitive Troponin-I; Abbott Diagnostics, Abbott Park, IL) was determined using chemiluminescent microparticle immunoassay on the ARCHITECT i2000SR analyzer (Abbott Laboratories, Singapore). The lower limit of detection (LOD) for NT-proBNP and hsTnI was 5 pg/mL and 1.1 ng/L, respectively.^{22,23} All biochemical concentrations lower than the detection levels were assigned a value equivalent to half the LOD.

Statistical analysis

Distribution of continuous variables was assessed using the Shapiro–Wilk test. Data were presented in either mean $\pm$ standard deviation or median (interquartile range), as appropriate. Depending on the normality of the distribution, parametric Student's *t*-test and one-way analysis of variance (ANOVA; with *post hoc* Bonferroni adjustment for pairwise comparison) or the non-parametric Mann–Whitney *U* test and Kruskal–Wallis test were used to compare groups of continuous data. Categorical data were compared using the χ^2 test.

Event-free survival curves associated with LVH patterns were estimated using the Kaplan–Meier method and compared with the log-rank test. The incremental prognostic values of RI (categorical) and CMR concentricity (categorical) over a model consisting of LVH (categorical), age, sex, and systolic blood pressure (SBP) were assessed using a change in the global χ^2 value for each model. Multivariable Cox proportional hazards models were used to adjust for potential confounders (age, sex, and SBP) and known markers of prognostic significance (wall thickness, CMR concentricity, global longitudinal strain, and echocardiographic RWT).

Statistical analyses were performed using GraphPad Prism Version 8 (GraphPad Software, Inc., San Diego, CA, USA) and SPSS Version 24 (IBM Corp., Armonk, NY, USA). A two-sided *P*-value <0.05 was considered as statistically significant.

Results

A total of 400 hypertensive patients (57 ± 11 years; 58% males; SBP 132 ± 15 mmHg) were recruited in this study. There were 176 patients with hypertensive LVH: 121 patients with normal RI and 55 with low RI. No patients with hypertensive LVH had higher than normal RI values in this cohort (Table 1).

Geometric profiles of hypertensive LVH

In patients with hypertensive LVH, concentric hypertrophy was the more prevalent geometric pattern ($n = 110$; 62.5%; Table 2). LV dilatation (based on age- and sex-specific reference ranges we have established in Asians²¹) was not a common feature, present in only 33 patients (18.8%) with hypertensive LVH. A similar number of patients with dilated LV had concentric ($n = 14$) and eccentric ($n = 19$) hypertrophy. Dilated concentric hypertrophy was most prevalent in younger males and associated with adverse features of LVH (highest LV mass, fibrosis burden, increased myocardial injury, and worst myocardial deformation). Conversely, non-dilated eccentric hypertrophy was most prevalent in older females and associated with more favourable characteristics of cardiac remodelling (Figure 2; Supplementary data online).

In a single measure, the RI describes the complex relationship between LV dilatation and concentricity associated with cardiac remodelling (Figure 2). In those with normal RI, 47.9% and 52.1% had concentric and eccentric hypertrophy, respectively. About 17% of these patients with normal RI had dilated LV. Concentric hypertrophy was the most common pattern in patients with hypertensive LVH and low RI ($n = 52$; 94.5%). Approximately one in five patients with low RI had a dilated LV, all of them had dilated concentric LVH pattern. Hypertensive LVH and low RI was more prevalent in younger males and associated with elevated blood pressures. Patients with hypertensive LVH and low RI had increased LV mass index, non-ischaemic myocardial fibrosis, reduced myocardial deformation, and elevated biochemical markers of myocardial injury (hsTnI) and cardiac decompensation (Table 1). Similar findings were observed after adjusting for age, sex, and SBP ($P < 0.001$ for all analyses).

Increasing severity of hypertensive LVH was associated with abnormalities in myocardial mechanics despite similar LV ejection fraction, a global measure of LV function. In early hypertensive LVH (normal RI), an initial reduction in myocardial deformation was associated with an increased in aortic peak flow acceleration; in more severe hypertensive LVH (low RI), further impairment in myocardial deformation was associated with no significant change in aortic peak flow acceleration, after adjusting for the effects of age, sex, and SBP (Figure 3).

Adverse cardiovascular outcomes

Complete follow-up data were available in all patients. During the 18.3 ± 7.0 months (601.3 patient-years) of follow-up, 14 adverse events occurred (2.2 events/100 patient-years): all-cause death ($n = 2$), non-fatal myocardial infarction ($n = 3$), non-fatal strokes ($n = 2$), decompensated heart failure ($n = 2$), and unstable angina (medical therapy, $n = 3$; invasive revascularization, $n = 2$).

The RI improved risk stratification of hypertensive LVH by identifying patients with high- and low-event rates. High-risk patients identified using the RI (corresponding to the 5th percentile for age and sex) had more than a five-fold increase in adverse events (11.6 events/100 patient-years vs. 2.0 events/100 patient-years, respectively; log rank $P < 0.001$; Figure 4), with 50% of the events occurring within the first year of follow-up. Hypertensive LVH and low RI was associated with increased rates of primary endpoint [hazard ratio (HR) 22.0; 95% confidence interval: 3.8–127.3], but hypertensive

Table 1 Clinical and cardiovascular magnetic resonance characteristics of hypertensive patients stratified by the remodelling index

	Hypertensive patients			P-value
	No LVH (n = 224)	LVH normal RI (n = 121)	LVH low RI (n = 55)	
Clinical characteristics				
Age (years)	58 ± 10 ^a	57 ± 11 ^b	50 ± 13	<0.0001
Males, n (%)	147 (66)	50 (41)	35 (64)	<0.0001
Height (m)	1.66 ± 0.08 ^c	1.63 ± 0.08 ^b	1.66 ± 0.10	0.006
Weight (kg)	71 ± 14 ^a	71 ± 17 ^b	78 ± 22	0.009
BSA (m ²)	1.79 ± 0.20	1.76 ± 0.21 ³	1.86 ± 0.27	0.012
Diabetes mellitus, n (%)	28 (13)	13 (11)	10 (18)	0.385
Hyperlipidaemia, n (%)	85 (38)	57 (47)	23 (42)	0.255
Systolic blood pressure (mmHg)	127 ± 13 ^{a,c}	134 ± 14 ^b	145 ± 16	<0.0001
Diastolic blood pressure (mmHg)	79 ± 9 ^a	80 ± 10 ^a	88 ± 10	<0.0001
Echo relative wall thickness	0.35 ± 0.07 ^a	0.36 ± 0.09 ^b	0.48 ± 0.11	<0.0001
HbA1c (%)	7.0 (6.7–7.6)	7.1 (6.6–8.6)	7.9 (7.0–8.4)	0.100
NT-proBNP (pg/mL)	30.2 (13.5–64.2)	41.8 (18.2–87.5)	110.5 (39.0–268)	<0.0001
High-sensitive troponin I (ng/L)	1.5 (0.9–3.0)	3.2 (1.6–5.8)	5.5 (2.8–10.5)	<0.0001
Cardiovascular magnetic resonance characteristics				
Indexed LV mass (g/m ²)	47 ± 7 ^{a,c}	59 ± 13 ^b	78 ± 22	<0.0001
Indexed LV mass (g/height ^{1.7})	36 ± 7 ^{a,c}	45 ± 12 ^b	61 ± 19	<0.0001
Indexed LV mass (g/height ^{2.7})	22 ± 4 ^{a,c}	28 ± 6 ^b	36 ± 11	<0.0001
Indexed LVEDV (mL/m ²)	69 ± 10 ^{a,c}	81 ± 17	79 ± 17	<0.0001
Indexed LVESV (mL/m ²)	27 ± 6 ^{a,c}	33 ± 14	33 ± 13	<0.0001
Indexed LVSV (mL/m ²)	43 ± 7 ^{a,c}	48 ± 8	46 ± 9	<0.0001
LVEF (%)	62 ± 6 ^a	60 ± 8	59 ± 9	0.021
LV mass/LVEDV ratio	0.69 ± 0.10 ^{a,c}	0.73 ± 0.10 ^b	0.98 ± 0.16	<0.0001
Maximal wall thickness (mm)	8.4 ± 1.4 ^{a,c}	9.0 ± 1.4 ^b	12.5 ± 2.1	<0.0001
Remodelling index	6.1 ± 1.0 ^a	5.9 ± 0.8 ^b	4.3 ± 0.6	<0.0001
Remodelling index, percentile specific for age and sex	47.3 ± 26.5 ^{a,c}	34.3 ± 19.4 ^b	3.8 ± 2.8	<0.0001
Circumferential strain (%)	-22.6 ± 3.0 ^{a,c}	-21.6 ± 3.6 ^b	-20.1 ± 4.4	<0.0001
Radial strain (%)	48.2 ± 12.6 ^{a,c}	43.7 ± 13.0	40.4 ± 15.0	<0.0001
Longitudinal strain (%)	-20.5 ± 12.1 ^{a,c}	-18.2 ± 3.1 ^b	-15.8 ± 3.9	<0.0001
Native T1 (ms)	1004 ± 24 ^{a,c}	1020 ± 28 ^b	1037 ± 34	<0.0001
ECV (%)	25.9 ± 2.2 ^a	26.5 ± 2.8	26.9 ± 3.0	0.018
Non-ischaemic myocardial fibrosis, n (%)	22 (10)	25 (21)	35 (65)	<0.0001
Interstitial volume (mL/m ²)	11.7 ± 2.0 ^{a,c}	14.9 ± 3.9 ^b	20.0 ± 6.3	<0.0001

BSA, body surface area; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LV, left ventricular; SV, stroke volume; ECV extracellular volume.

^aANOVA post hoc Bonferroni adjustment: $P < 0.05$ between no LVH and LVH low RI.^bANOVA post hoc Bonferroni adjustment: $P < 0.05$ between LVH normal RI and LVH low RI.^cANOVA post hoc Bonferroni adjustment: $P < 0.05$ between no LVH and LVH normal RI.

LVH and normal RI was not (HR 4.5; 95% confidence interval: 0.7–28.0; [Supplementary data](#) online).

Although the survival distributions across the four conventional geometric patterns (normal, concentric remodelling, concentric, and eccentric hypertrophy) were statistically significant (log rank $P < 0.01$), both concentric and eccentric LVH had similar event rates (4.5 events/100 patient-years vs. 6.0 events/100 patient-years, respectively; log rank $P = 0.62$) compared to the natural history of LVH (5.1 events/100 patient-years; [Figure 4](#)). Eccentric hypertrophy was associated with increased rates of primary outcomes (HR 8.8; 95% confidence interval 1.6–48.3) but concentric hypertrophy was not

after adjusting for potential confounders (HR 4.7; 95% confidence interval 0.8–28.1; [Supplementary data](#) online).

Potential incremental prognostic value of the RI

Concentricity did not provide incremental prognostic value to LVH and other clinical variables: age, sex, and SBP. Conversely, the RI provided incremental prognostic value over and above the clinical model, LVH, and CMR concentricity ([Figure 4](#)). Similar findings were observed with RWT analysed in place of CMR concentricity. Furthermore, multivariable cox regression models

Table 2 Clinical and cardiovascular magnetic resonance characteristics of hypertensive patients stratified by the left ventricular mass and concentricity

	Hypertensive patients				P-value
	Normal (n = 182)	Concentric remodelling (n = 42)	Concentric LVH (n = 110)	Eccentric LVH (n = 66)	
Clinical characteristics					
Age (years)	59 ± 9 ^a	55 ± 10	54 ± 12	57 ± 10	0.001
Males, n (%)	120 (66)	27 (64)	57 (52)	28 (42)	0.003
Height (m)	1.66 ± 0.08	1.65 ± 0.07	1.64 ± 0.09	1.63 ± 0.08	0.215
Weight (kg)	70 ± 14 ^{a,b}	78 ± 15	75 ± 20	70 ± 16	0.004
BSA (m ²)	1.77 ± 0.20	1.85 ± 0.19	1.81 ± 0.25	1.75 ± 0.20	0.048
Diabetes mellitus, n (%)	24 (13)	4 (10)	15 (14)	8 (12)	0.913
Hyperlipidaemia, n (%)	69 (38)	16 (38)	48 (44)	32 (49)	0.441
Systolic blood pressure (mmHg)	126 ± 12 ^{a,b}	133 ± 15 ^c	141 ± 14 ^d	131 ± 16	<0.0001
Diastolic blood pressure (mmHg)	78 ± 9 ^{a,b}	83 ± 10	84 ± 11 ^d	79 ± 11	<0.0001
Echo relative wall thickness	0.34 ± 0.07 ^a	0.36 ± 0.07 ^c	0.43 ± 0.12 ^d	0.35 ± 0.08	<0.0001
HbA1c (%)	6.9 (6.6–7.4)	7.3 (6.9–8.0)	7.6 (7.0–8.2)	6.8 (6.6–8.9)	0.251
NT-proBNP (pg/mL)	30.2 (14.9–68.3)	30.3 (6.1–53.3)	66.3 (23.3–182.9)	42.9 (28.1–109.3)	<0.0001
High-sensitive troponin I (ng/L)	1.5 (0.6–2.9)	1.7 (1.3–3.4)	3.9 (2.3–8.7)	3.7 (1.5–6.6)	<0.0001
Cardiovascular magnetic resonance characteristics					
Indexed LV mass (g/m ²)	46 ± 7 ^{a,e}	51 ± 8 ^{c,f}	69 ± 20 ^d	58 ± 13	<0.0001
Indexed LVEDV (mL/m ²)	71 ± 9 ^{a,b,e}	62 ± 7 ^{c,f}	77 ± 16 ^d	87 ± 17	<0.0001
Indexed LVESV (mL/m ²)	28 ± 6 ^{a,b,e}	23 ± 6 ^{c,f}	31 ± 13 ^d	37 ± 15	<0.0001
Indexed LVSV (mL/m ²)	44 ± 7 ^{b,e}	39 ± 6 ^{c,f}	46 ± 8 ^d	50 ± 9	<0.0001
LVEF (%)	61 ± 6	63 ± 7 ^f	60 ± 9	59 ± 9	0.017
LV mass/LVEDV ratio	0.66 ± 0.08 ^{a,b}	0.83 ± 0.09 ^{c,f}	0.89 ± 0.15 ^d	0.67 ± 0.08	<0.0001
Maximal wall thickness (mm)	8.1 ± 1.2 ^{a,b,e}	9.6 ± 1.4 ^c	10.8 ± 2.4 ^d	8.9 ± 1.7	<0.0001
Remodelling index	6.3 ± 0.9 ^{a,b}	5.1 ± 0.6 ^f	4.9 ± 0.9 ^d	6.1 ± 0.9	<0.0001
Circumferential strain (%)	-22.6 ± 2.9 ^a	-22.7 ± 3.4 ^c	-20.9 ± 4.1	-21.4 ± 3.8	<0.0001
Radial strain (%)	48.1 ± 12.0 ^a	48.6 ± 15.4	42.3 ± 14.2	43.1 ± 13.0	0.001
Longitudinal strain (%)	-19.8 ± 3.0 ^a	-19.2 ± 3.8 ^c	-17.0 ± 3.7	-18.0 ± 3.3	<0.0001
Native T1 (ms)	1004 ± 25 ^{a,e}	1007 ± 22 ^{c,f}	1026 ± 32	1023 ± 28	<0.0001
ECV (%)	26.1 ± 2.2	25.2 ± 2.4 ^{c,f}	26.6 ± 3.0	26.6 ± 2.7	0.013
Non-ischaemic myocardial fibrosis, n (%)	15 (8)	7 (17)	48 (44)	12 (18)	<0.0001
Interstitial volume (mL/m ²)	11.5 ± 1.8 ^{a,e}	12.3 ± 1.7 ^{c,f}	17.5 ± 5.8 ^d	14.9 ± 3.9	<0.0001

BSA, body surface area; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LV, left ventricular; SV, stroke volume; ECV extracellular volume.

^aANOVA post hoc Bonferroni adjustment: $P < 0.05$ between no LVH and concentric LVH.^bANOVA post hoc Bonferroni adjustment: $P < 0.05$ between no LVH and concentric remodelling.^cANOVA post hoc Bonferroni adjustment: $P < 0.05$ between concentric remodelling and concentric LVH.^dANOVA post hoc Bonferroni adjustment: $P < 0.05$ between concentric and eccentric LVH.^eANOVA post hoc Bonferroni adjustment: $P < 0.05$ between no LVH and eccentric LVH.^fANOVA post hoc Bonferroni adjustment: $P < 0.05$ between concentric remodelling and eccentric LVH.

demonstrated that the RI was associated with worse prognosis independent of age, sex, SBP and LVH, and other prognostic markers, such as CMR concentricity, RWT, wall thickness, and (trend towards statistical significance) global longitudinal strain (Table 3; Supplementary data online).

Discussion

The RI is an integrated measure that describes the heterogeneous remodelling effects of hypertensive LVH. In a large CMR cohort of

400 well-characterized hypertensive patients, we demonstrated that LVH with low RI was associated with features of maladaptive cardiac remodelling: increased LV mass, non-ischaemic myocardial fibrosis, impaired myocardial deformation, elevated biochemical markers of myocardial injury (hsTnI) and cardiac wall stress. Unlike the conventional LVH classification (concentric and eccentric hypertrophy), the RI improved risk stratification of hypertensive LVH. Hypertensive patients with LVH and low RI had more than five-fold increase in event rates compared to those with LVH and normal RI. The RI provided incremental prognostic value to an established model of clinical variables and LVH; and predicted





Figure 2 Geometric patterns of hypertensive left ventricular hypertrophy (A) and after classification by the remodelling index (B).



In the presence of increased afterload from elevated pressures, LVH was initially adaptive to minimise wall stress and maintain cardiac output. Subsequently, the LV decompensates.²⁸ While the conventional LVH classification is meaningful to describe mechanical wall

In addition to being a marker of advanced hypertrophy, the RI improved risk stratification of hypertensive LVH by identifying patients at high and low risk for adverse cardiovascular events. Patients with LVH and low RI had over a five-fold increase in event rate compared to those with normal RI. Moreover, the RI (but not concentricity or RWT) provided incremental prognostic value over clinical variables and LVH. In the proposed four-group LVH classification, dilated concentric had the highest risk and non-dilated eccentric hypertrophy was associated with the most favourable prognosis.²⁴⁻²⁷ Consistent with these observations, in our study, all but two patients with dilated concentric hypertrophy (85.7%) had low RI, our classification of high-risk phenotype; conversely, all but three patients with non-dilated eccentric hypertrophy (93.8%) had normal RI (low-risk phenotype).

Hypertensive LVH is a heterogeneous condition and the individual risk of adverse outcomes is variable. Therefore, it is critical to




Figure 4 Event-free survival associated with left ventricular hypertrophy stratified by the remodelling index (A) and conventional geometric classification (B). Incremental prognostic value of the remodelling index compared with conventional markers (C).

efficiently identify and prioritise high-risk patients for intensified therapies. Our study supports existing evidence and endorses the importance of assessing LV dilatation and concentricity as important mediators of cardiac remodelling. The RI simplifies the four-group LVH classification into a single measure that is easy to apply.

In the previous studies, the two highest risk groups in the proposed four-group LVH classification accounted for 8–37% of all the adverse events observed,^{25,27} with a lack of incremental value demonstrated in one study.²⁶ Using the RI, about 30% of patients with hypertensive LVH were stratified as high risk that accounted

for more than 60% of the events observed. These high-risk patients may potentially derive the most benefits from aggressive management and targeted treatment, while unnecessary treatment and investigations can be avoided in the lower risk patients. The application of the RI and these findings should be validated in other populations.

Recommending CMR in all patients with hypertensive LVH is not practical. Cost-effective strategies to integrate the RI into clinical practice and its role with other more widely available biomarkers of cardiac remodelling should be investigated in future studies.

Table 3 Hazard ratios predicting adverse cardiovascular events for the remodelling index in adjusted and unadjusted analyses

Model	Hazard ratio (95% confidence interval)
Unadjusted model	5.96 (2.77–12.83)
Model 1: Age, sex, systolic blood pressure, LVH (categorical)	3.55 (1.13–11.18)
Model 2: Model 1 + CMR concentricity (categorical)	5.03 (1.62–15.59)
Model 3: Model 1 + RWT (echo)	4.84 (1.32–17.78)
Model 4: Model 1 + wall thickness	4.11 (1.33–12.65)
Model 5: Model 1 + global longitudinal strain	3.16 (0.91–10.95)

Study limitations

The number of events is relatively small due to the low-risk cohort of asymptomatic hypertensive patients that was studied. However, the event rate observed in our study (2.0 events/100 patient-years) was comparable to those reported in previous studies.^{2,3} We were not able to examine the prognostic interactions between LV dilatation and concentricity because of the limited number of patients with dilated LV in our cohort. The RI assumes a spherical LV that may be insensitive to the effects of chamber dilatation. We had used a spherical model because the radius can be estimated accurately from LVEDV on routine CMR. Conversely, the use of an ellipsoid model requires at least two linear measurements in 1–2 cardiac views to estimate radius. This will not only increase the complexity but also introduce variations in measurements and calculations. Regardless of the model used, we acknowledged that each was associated with systematic differences in estimating wall stresses.

Conclusions

Hypertensive LVH is a heterogeneous remodelling process mediated by increased concentricity and LV dilatation. The RI provides mechanistic insights and as a single measure, it is a convenient approach of risk stratifying patients with hypertensive LV hypertrophy.

Supplementary data

Supplementary data are available at *European Heart Journal - Cardiovascular Imaging* online.

Acknowledgements

The authors thank the radiographers at the Department of Cardiovascular Magnetic Resonance Imaging, National Heart Center Singapore for performing the CMR in the study; and Abbott Diagnostics for providing the high-sensitive cardiac troponin I reagents and controls.

Funding

The study was supported by the National Medical Research Council, Singapore.

Conflict of interest: none declared.

References

1. Vakil BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. *Am Heart J* 2001;**141**:334–41.

2. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. *J Am Coll Cardiol* 2001;**38**:1829–35.

3. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. *Hypertension* 2000;**35**:580–6.

4. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. *J Am Coll Cardiol* 1992;**19**:1550–8.

5. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). *Eur Heart J Cardiovasc Imaging* 2015;**16**:577–605.

6. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. *J Am Coll Cardiol* 1995;**25**:879–84.

7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. *Am J Cardiol* 1996;**78**:197–202.

8. Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S. Left ventricular mass and geometry and the risk of ischemic stroke. *Stroke* 2003;**34**:2380–4.

9. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. *J Am Coll Cardiol* 1998;**31**:1635–40.

10. Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. *Am J Cardiol* 2013;**112**:1158–64.

11. Paoletti E, De Nicola L, Gabbai FB, Chiodini P, Ravera M, Pieracci L et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. *Clin J Am Soc Nephrol* 2016;**11**:271–9.

12. Goh V, Le TT, Bryant JA, Wong JI, Su B, Lee CH et al. Novel index of maladaptive myocardial remodeling in hypertension. *Circ Cardiovasc Imaging* 2017;**10**:1–19.

13. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. *J Magn Reson Imaging* 2007;**26**:1081–6.

14. Mewton N, Liu CY, Croisille P, Bluemke D, Lima J. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. *J Am Coll Cardiol* 2011;**57**:891–903.

15. Chin C, Semple S, Malley T, White AC, Mirsadraee S, Weale P et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. *Eur Heart J Cardiovasc Imaging* 2014;**15**:556–65.

16. Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. *JACC Cardiovasc Imaging* 2017;**10**:1320–33.

17. Cai J, Bryant JA, Le TT, Su B, de Marva A, O'Regan DP et al. Fractal analysis of left ventricular trabeculations is associated with impaired myocardial deformation in healthy Chinese. *J Cardiovasc Magn Reson* 2017;**19**:102.

18. Hunt AC, Chow SL, Escaned J, Perry RA, Seth A, Shiu MF. Evaluation of a theoretical Doppler index to noninvasively estimate peak dP/dt using continuous wave Doppler ultrasound of ascending aortic flow in man. *Cathet Cardiovasc Diagn* 1991;**23**:219–22.

19. Bauer F, Jones M, Shiota T, Firstenberg MS, Qin JX, Tsujino H et al. Left ventricular outflow tract mean systolic acceleration as a surrogate for the slope of the left ventricular end-systolic pressure-volume relationship. *J Am Coll Cardiol* 2002;**40**:1320–7.

20. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande J et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015;**16**:233–70.

21. Le TT, Tan RS, De Deyn M, Goh EP, Han Y, Leong BR et al. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. *J Cardiovasc Magn Reson* 2016;**18**:21.
22. Roche NT-pro BNP assay [Package insert]. 2006.
23. Abbott STAT High Sensitive Troponin-I [Package insert]. 2012.
24. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. *Circ Cardiovasc Imaging* 2010;**3**:164–71.
25. Bang CN, Gerds E, Aurigemma GP, Boman K, de Simone G, Dahlof B et al. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. *Circ Cardiovasc Imaging* 2014;**7**:422–9.
26. de Simone G, Izzo R, Aurigemma GP, De Marco M, Rozza F, Trimarco V et al. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. *J. Hypertens* 2015;**33**:745–54.
27. Garg S, de Lemos JA, Ayers C, Khouri MG, Pandey A, Berry JD et al. Association of a 4-tiered classification of LV hypertrophy with adverse CV outcomes in the general population. *JACC Cardiovasc Imaging* 2015;**8**:1034–41.
28. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation* 2000;**102**:470–9.